| Description |
Recombinant Mouse PCSK9 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln35-Gln694. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
Q80W65 |
| Target Symbol |
PCSK9 |
| Synonyms |
PC9; PCSK9; FH3; HCHOLA3; LDLCQ1; NARC-1 |
| Species |
Mouse |
| Expression System |
HEK293 |
| Tag |
C-His |
| Expression Range |
Gln35-Gln694 |
| Mol. Weight |
Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-68 kDa (pro-form) and 15kDa (mature form) based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in 20mM Tris, 150mM NaCL, 200mM L-Aginine (pH 8.2). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Activity |
The affinity constant of 0.61 nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated. |
